<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">Immunovaccine Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:8c032c65-72a0-4a1c-8cc7-d2c0ddbfd8a0;id=42165</id>
  <rights
    type="text">Copyright 2017, Immunovaccine Inc.</rights>
  <updated>2017-05-16T11:05:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/KNiCoGagdCPIE9cqneV8Mg==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/KNiCoGagdCPIE9cqneV8Mg==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/05/16/1010127/0/en/Immunovaccine-s-Lead-Immuno-Oncology-Candidate-to-Enter-Investigator-Sponsored-Phase-2-Clinical-Trial-in-DLBCL-in-Combination-with-Approved-Anti-PD-1-Drug.html</id>
    <title
      type="text">Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug</title>
    <published>2017-05-16T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/05/16/1010127/0/en/Immunovaccine-s-Lead-Immuno-Oncology-Candidate-to-Enter-Investigator-Sponsored-Phase-2-Clinical-Trial-in-DLBCL-in-Combination-with-Approved-Anti-PD-1-Drug.html" />
    <content
      type="html"><![CDATA[<p><em><p>Company's Clinical Program Continues to Expand with Second Phase 2 Trial Announced This Year Evaluating the Combination of DPX-Survivac and Anti-PD-1 Therapies in Hard-to-Treat Cancers</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - May 16, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that an investigator-sponsored Phase 2 clinical trial will evaluate the use of a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B-Cell lymphoma (DLBCL). Investigators will assess the efficacy and safety of Immunovaccine's lead candidate, DPX-Survivac, along with a checkpoint inhibitor drug currently marketed by a large pharmaceutical company, and low-dose cyclophosphamide. Immunovaccine expects the trial to begin enrolling patients following receipt of regulatory clearance from Health Canada.</p>]]></content>
    <dc:identifier>1010127</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/05/10/1010125/0/en/Immunovaccine-Announces-Financial-Results-for-Quarter-Ended-March-31-2017.html</id>
    <title
      type="text">Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017</title>
    <published>2017-05-10T21:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/05/10/1010125/0/en/Immunovaccine-Announces-Financial-Results-for-Quarter-Ended-March-31-2017.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today released its financial and operational results for the first quarter ended March 31, 2017. </p>]]></content>
    <dc:identifier>1010125</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/05/02/1010124/0/en/Immunovaccine-to-Present-at-19th-Annual-TIDES-Oligonucleotide-and-Peptide-Therapeutics-Conference.html</id>
    <title
      type="text">Immunovaccine to Present at 19th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference</title>
    <published>2017-05-02T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/05/02/1010124/0/en/Immunovaccine-to-Present-at-19th-Annual-TIDES-Oligonucleotide-and-Peptide-Therapeutics-Conference.html" />
    <content
      type="html"><![CDATA[<p><em><p>Researchers Will Highlight DepoVax(TM) Vaccine Delivery Platform's Novel Applications in Ovarian Cancer and Respiratory Syncytial Virus (RSV)</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - May 2, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the company's Vice President of Product Development and Manufacturing <a rel="nofollow" href="https://www.imvaccine.com/team_management.php?bios_id=70" title="Leeladhar Sammatur">Leeladhar Sammatur</a> will present research at the <a rel="nofollow" href="https://lifesciences.knect365.com/tides/" title="19th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference">19th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference</a> in San Diego, Calif. His presentation will focus on the commercial potential enabled by the Company's proprietary DepoVax&#8482; platform formulations. Specifically, he will discuss how the Company translated the unique pharmacokinetics that were facilitated by antigens encapsulated in nanoparticles and suspended in oil - a signature of the DepoVax&#8482; platform - into novel clinical candidates in immuno-oncology (DPX-Survivac) and infectious diseases (DPX-RSV). </p>]]></content>
    <dc:identifier>1010124</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/18/1010123/0/en/Immunovaccine-Announces-Dosing-of-First-Patient-in-Investigator-Sponsored-Phase-1b-2-Clinical-Trial-Evaluating-Immuno-Oncology-Candidate-Targeting-Incurable-HPV-Related-Cancers.html</id>
    <title
      type="text">Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers</title>
    <published>2017-04-18T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/18/1010123/0/en/Immunovaccine-Announces-Dosing-of-First-Patient-in-Investigator-Sponsored-Phase-1b-2-Clinical-Trial-Evaluating-Immuno-Oncology-Candidate-Targeting-Incurable-HPV-Related-Cancers.html" />
    <content
      type="html"><![CDATA[<p><em><p>Study Demonstrates Broad Applicability of Immunovaccine's DepoVax(TM) Platform for Delivering Cancer Antigens</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - April 18, 2017) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that the first study participant has been treated in a Phase 1b/2 clinical study evaluating Immunovaccine's investigational cancer vaccine, DPX-E7, in combination with low-dose cyclophosphamide in patients with incurable oropharyngeal, cervical and anal cancers related to the human papillomavirus (HPV). </p>]]></content>
    <dc:identifier>1010123</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/12/1010121/0/en/Immunovaccine-Announces-Positive-Year-Long-Immunogenicity-Data-from-Phase-1-Clinical-Trial-for-Respiratory-Syncytial-Virus-Vaccine-Candidate.html</id>
    <title
      type="text">Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate</title>
    <published>2017-04-12T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/12/1010121/0/en/Immunovaccine-Announces-Positive-Year-Long-Immunogenicity-Data-from-Phase-1-Clinical-Trial-for-Respiratory-Syncytial-Virus-Vaccine-Candidate.html" />
    <content
      type="html"><![CDATA[<p><em><p>100 Percent of Healthy Older Adult Volunteers Who Responded to Vaccine Achieved a Sustained Antigen-Specific Immune Response that Remains at Peak One Year Post-Vaccination with DPX-RSV; This Level of Response with a Low-dose Volume of a Small Peptide is Groundbreaking and Highlights Potential of DepoVax(TM) Platform</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - April 12, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced updated data on its investigator-sponsored Phase 1 clinical trial testing the safety and immunogenicity of its DepoVax&#8482;-based, small B-cell epitope peptide vaccine candidate for respiratory syncytial virus (RSV). In the 25 &#181;g dose cohort, which was the only dose tested out to one year, 100 percent of older adults (7/7 immune responders) vaccinated with DPX-RSV maintained the antigen-specific immune responses one year after receiving the booster dose. At one year, the antibody levels measured were still at peak with no sign of decrease. The 25 &#181;g dose was delivered in a volume of 50 microliters. A standard flu vaccine is typically 60 &#181;g delivered in 10 times this volume. </p>]]></content>
    <dc:identifier>1010121</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/11/1010120/0/en/Princess-Margaret-Cancer-Center-Receives-Health-Canada-Clearance-to-Begin-Investigator-Sponsored-Phase-2-Ovarian-Cancer-Study-Evaluating-Immunovaccine-s-DPX-Survivac-with-Merck-s-P.html</id>
    <title
      type="text">Princess Margaret Cancer Center Receives Health Canada Clearance to Begin Investigator-Sponsored Phase 2 Ovarian Cancer Study Evaluating Immunovaccine's DPX-Survivac with Merck's Pembrolizumab</title>
    <published>2017-04-11T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/11/1010120/0/en/Princess-Margaret-Cancer-Center-Receives-Health-Canada-Clearance-to-Begin-Investigator-Sponsored-Phase-2-Ovarian-Cancer-Study-Evaluating-Immunovaccine-s-DPX-Survivac-with-Merck-s-P.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - April 11, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that University Health Network's <a rel="nofollow" href="http://www.uhn.ca/PrincessMargaret" title="Princess Margaret Cancer Centre">Princess Margaret Cancer Centre</a> (PM) has received Health Canada clearance to initiate a clinical study evaluating immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada). The Phase 2 triple-combination therapy trial is designed to evaluate the potential anti-tumor activity of Merck's pembrolizumab with Immunovaccine's lead cancer vaccine candidate, DPX-Survivac, in patients with recurrent, platinum-resistant ovarian cancer. Patients will also receive low-dose cyclophosphamide.</p>]]></content>
    <dc:identifier>1010120</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/07/1010119/0/en/Immunovaccine-to-Present-at-Bloom-Burton-Co-Healthcare-Investor-Conference.html</id>
    <title
      type="text">Immunovaccine to Present at Bloom Burton &amp; Co. Healthcare Investor Conference</title>
    <published>2017-04-07T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/07/1010119/0/en/Immunovaccine-to-Present-at-Bloom-Burton-Co-Healthcare-Investor-Conference.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - April 7, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that <a rel="nofollow" href="https://www.imvaccine.com/team_management.php?bios_id=53" title="Chief Executive Officer Frederic Ors">Chief Executive Officer Frederic Ors</a> will present an update on the Company's recent progress and future strategy at the <a rel="nofollow" href="https://www.bloomburton.com/conference/" title="Bloom Burton &amp; Co. Healthcare Investor Conference 2017">Bloom Burton &amp; Co. Healthcare Investor Conference 2017</a> in Toronto, Canada.</p>]]></content>
    <dc:identifier>1010119</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/04/05/1010117/0/en/Immunovaccine-Inc-Presents-Preclinical-Research-at-AACR-2017-on-Ability-of-Novel-Monoclonal-Antibodies-to-Boost-Efficacy-of-DepoVax-TM-based-Cancer-Immunotherapy.html</id>
    <title
      type="text">Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy</title>
    <published>2017-04-05T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/04/05/1010117/0/en/Immunovaccine-Inc-Presents-Preclinical-Research-at-AACR-2017-on-Ability-of-Novel-Monoclonal-Antibodies-to-Boost-Efficacy-of-DepoVax-TM-based-Cancer-Immunotherapy.html" />
    <content
      type="html"><![CDATA[<p><em><p>Study Part of Ongoing Effort to Identify Novel Combinations of DepoVax(TM)-based Immuno-oncology Candidates to Improve the Responses of Other Novel Immunotherapy Agents</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - April 5, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that new preclinical data presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting demonstrated that phosphatidylserine (PS) targeting antibodies can enhance the anti-cancer activity of its DepoVax&#8482;-based therapeutic vaccine platform.</p>]]></content>
    <dc:identifier>1010117</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/03/30/1010116/0/en/Immunovaccine-Announces-2016-Year-End-Results.html</id>
    <title
      type="text">Immunovaccine Announces 2016 Year-End Results</title>
    <published>2017-03-30T21:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/03/30/1010116/0/en/Immunovaccine-Announces-2016-Year-End-Results.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - March 30, 2017) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Corporation") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2016.</p>]]></content>
    <dc:identifier>1010116</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/03/29/1010114/0/en/Immunovaccine-Announces-Positive-Interim-Clinical-Data-from-Ovarian-Cancer-Study-of-DPX-Survivac-in-Combination-with-Epacadostat.html</id>
    <title
      type="text">Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat</title>
    <published>2017-03-29T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/03/29/1010114/0/en/Immunovaccine-Announces-Positive-Interim-Clinical-Data-from-Ovarian-Cancer-Study-of-DPX-Survivac-in-Combination-with-Epacadostat.html" />
    <content
      type="html"><![CDATA[<p><em><p>Preliminary Analysis Supports the Ability of Immunovaccine's Lead Candidate to Induce T-Cell Infiltration</p><p></p><p>Early Data Reflect Tolerability and Clinical Potential of the Triple Combination Immunotherapy in Recurrent Ovarian Cancer</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - March 29, 2017) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the first interim data analysis from its <a rel="nofollow" href="https://www.imvaccine.com/releases.php?releases_id=400" title="ongoing Phase 1b clinical study">ongoing Phase 1b clinical study</a> of its novel T-cell activating immuno-oncology candidate, DPX-Survivac, in combination with epacadostat and low-dose cyclophosphamide. The analysis included the results of blood tests, tumor biopsies and CT scans to assess safety, disease progression and T-cell response for the first four evaluable patients in the trial.</p>]]></content>
    <dc:identifier>1010114</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/03/24/1010113/0/en/Immunovaccine-to-Present-New-Pre-clinical-Combination-Therapy-Data-at-the-AACR-Annual-Meeting.html</id>
    <title
      type="text">Immunovaccine to Present New Pre-clinical Combination Therapy Data at the AACR Annual Meeting</title>
    <published>2017-03-24T11:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/03/24/1010113/0/en/Immunovaccine-to-Present-New-Pre-clinical-Combination-Therapy-Data-at-the-AACR-Annual-Meeting.html" />
    <content
      type="html"><![CDATA[<p><em><p>Study Designed to Assess Synergies of Combining DepoVax(TM)-based Cancer Vaccines and Novel Monoclonal Antibody Immunotherapies</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - March 24, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that new pre-clinical data on DepoVax&#8482;-based cancer vaccines will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017, which will be held in Washington, D.C., from April 1-5.</p>]]></content>
    <dc:identifier>1010113</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/02/06/1010112/0/en/Immunovaccine-s-Lead-Immuno-Oncology-Candidate-to-Enter-Investigator-Sponsored-Phase-2-Clinical-Trial-in-Ovarian-Cancer-in-Combination-With-Approved-Anti-PD-1-Drug.html</id>
    <title
      type="text">Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in Ovarian Cancer in Combination With Approved Anti-PD-1 Drug</title>
    <published>2017-02-06T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/02/06/1010112/0/en/Immunovaccine-s-Lead-Immuno-Oncology-Candidate-to-Enter-Investigator-Sponsored-Phase-2-Clinical-Trial-in-Ovarian-Cancer-in-Combination-With-Approved-Anti-PD-1-Drug.html" />
    <content
      type="html"><![CDATA[<p><em><p>University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined With DPX-Survivac</p></em></p><p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Feb. 6, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the UHN's <a rel="nofollow" href="http://www.uhn.ca/PrincessMargaret" title="Princess Margaret Cancer Centre">Princess Margaret Cancer Centre </a>(PM) will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada). </p>]]></content>
    <dc:identifier>1010112</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/02/03/1010110/0/en/Immunovaccine-Appoints-Seasoned-Financial-Executive-Pierre-Labbe-as-CFO.html</id>
    <title
      type="text">Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO</title>
    <published>2017-02-03T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/02/03/1010110/0/en/Immunovaccine-Appoints-Seasoned-Financial-Executive-Pierre-Labbe-as-CFO.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Feb. 3, 2017) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced Pierre Labb&#233;, CPA, CA, ICD, will join the Company as Chief Financial Officer (CFO), effective February 20, 2017. In this role, Mr. Labb&#233; will be responsible for leading the company's financial strategy and operations, with an emphasis on expanding financing and business development operations as the Company continues to advance its clinical program and expand its pipeline.</p>]]></content>
    <dc:identifier>1010110</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/02/02/1010109/0/en/Immunovaccine-to-Present-at-2017-BIO-CEO-Investor-Conference.html</id>
    <title
      type="text">Immunovaccine to Present at 2017 BIO CEO &amp; Investor Conference</title>
    <published>2017-02-02T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/02/02/1010109/0/en/Immunovaccine-to-Present-at-2017-BIO-CEO-Investor-Conference.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Feb. 2, 2017) -</strong> Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in this year's <a rel="nofollow" href="https://www.bio.org/events/bio-ceo-investor-conference" title="BIO CEO and Investor Conference">BIO CEO and Investor Conference</a> in New York, NY. This event takes place February 13-14, 2017 at the Waldorf Astoria Hotel.</p>]]></content>
    <dc:identifier>1010109</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2017/01/04/1010107/0/en/Immunovaccine-to-Present-at-2017-Biotech-Showcase-Conference.html</id>
    <title
      type="text">Immunovaccine to Present at 2017 Biotech Showcase Conference</title>
    <published>2017-01-04T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2017/01/04/1010107/0/en/Immunovaccine-to-Present-at-2017-Biotech-Showcase-Conference.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Jan. 4, 2017) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in the <a rel="nofollow" href="https://ebdgroup.knect365.com/biotech-showcase/" title="9th Annual Biotech Showcase Conference">9th Annual Biotech Showcase Conference</a> in San Francisco, CA. This event takes place January 9-11, 2017, at the Hilton San Francisco Union Square.</p>]]></content>
    <dc:identifier>1010107</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/12/09/1010105/0/en/Immunovaccine-Announces-Closing-of-8-Million-Bought-Deal-Private-Placement-Financing.html</id>
    <title
      type="text">Immunovaccine Announces Closing of $8 Million Bought Deal Private Placement Financing</title>
    <published>2016-12-09T14:23:01Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/12/09/1010105/0/en/Immunovaccine-Announces-Closing-of-8-Million-Bought-Deal-Private-Placement-Financing.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Dec. 9, 2016) -</strong> </p>]]></content>
    <dc:identifier>1010105</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/11/23/1010104/0/en/Immunovaccine-Inc-IMV-T-8-Million-Bought-Deal-Private-Placement-Financing.html</id>
    <title
      type="text">Immunovaccine Inc. ("IMV-T") - $8 Million Bought Deal Private Placement Financing</title>
    <published>2016-11-23T22:09:11Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/11/23/1010104/0/en/Immunovaccine-Inc-IMV-T-8-Million-Bought-Deal-Private-Placement-Financing.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 23, 2016) -</strong> </p>]]></content>
    <dc:identifier>1010104</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/11/22/1010103/0/en/The-European-Medicines-Agency-Grants-Orphan-Drug-Designation-Status-to-Immunovaccine-s-DPX-Survivac-in-Ovarian-Cancer.html</id>
    <title
      type="text">The European Medicines Agency Grants Orphan Drug Designation Status to Immunovaccine's DPX-Survivac in Ovarian Cancer</title>
    <published>2016-11-22T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/11/22/1010103/0/en/The-European-Medicines-Agency-Grants-Orphan-Drug-Designation-Status-to-Immunovaccine-s-DPX-Survivac-in-Ovarian-Cancer.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 22, 2016) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that the European Medicines Agency ("EMA") has granted 'Orphan Drug Designation' status to the Company's lead immuno-oncology product candidate, DPX-Survivac for the treatment of ovarian cancer in the European Union (EU). </p>]]></content>
    <dc:identifier>1010103</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/11/14/1010101/0/en/Immunovaccine-to-Present-at-2016-Biotech-Money-Showcase-Conference.html</id>
    <title
      type="text">Immunovaccine to Present at 2016 Biotech &amp; Money Showcase Conference</title>
    <published>2016-11-14T12:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/11/14/1010101/0/en/Immunovaccine-to-Present-at-2016-Biotech-Money-Showcase-Conference.html" />
    <content
      type="html"><![CDATA[<p><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 14, 2016) -</strong> Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in the <a rel="nofollow" href="http://www.biotechandmoney.com/investival-showcase?__hstc=165520288.43782c4d4d09676fd131d6c17c6c49c3.1477336244749.1477336244749.1477479268287.2&amp;__hssc=165520288.1.1478708421769&amp;__hsfp=1121307574&amp;hsCtaTracking=002380d3-3fad-4d39-855e-96adbc695265%7C3884420b-5fa6-4d89-996a-ea2fc0dd6b11" title="2016 Biotech &amp; Money Investival Showcase">2016 Biotech &amp; Money Investival Showcase</a> in London, England. This event is a corporate, investor and networking conference, co-located with the Jefferies 2016 London Healthcare Conference, that gives private and public life sciences companies an opportunity to meet investors and pharmaceutical executives.</p>]]></content>
    <dc:identifier>1010101</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/11/08/1010100/0/en/Immunovaccine-Announces-Third-Quarter-2016-Financial-Results-and-Provides-Corporate-Update.html</id>
    <title
      type="text">Immunovaccine Announces Third Quarter 2016 Financial Results and Provides Corporate Update</title>
    <published>2016-11-08T22:05:00Z</published>
    <updated>2024-11-08T20:40:58Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/11/08/1010100/0/en/Immunovaccine-Announces-Third-Quarter-2016-Financial-Results-and-Provides-Corporate-Update.html" />
    <content
      type="html"><![CDATA[<p style="border-bottom: medium none; border-left: medium none; border-top: medium none; border-right: medium none;"><strong>HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 8, 2016) -</strong> Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today announced financial results for the third quarter ended September 30, 2016 and provided a corporate update. </p>]]></content>
    <dc:identifier>1010100</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Immunovaccine Inc.</dc:contributor>
    <dc:modified>Tue, 12 Sep 2017 12:01 GMT</dc:modified>
  </entry>
</feed>